Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Acquisitions & Divestments: 2017-2024

Historic Change in Acquisitions & Divestments for Coherus Oncology (CHRS) over the last 1 years, with Mar 2024 value amounting to $8.7 million.

  • Coherus Oncology's Change in Acquisitions & Divestments fell 50.35% to $8.7 million in Q1 2024 from the same period last year, while for Mar 2024 it was $135.5 million, marking a year-over-year decrease of 56.72%. This contributed to the annual value of $8.7 million for FY2024, which is 93.98% down from last year.
  • As of Q1 2024, Coherus Oncology's Change in Acquisitions & Divestments stood at $8.7 million, which was down 76.01% from $36.2 million recorded in Q4 2023.
  • Coherus Oncology's Change in Acquisitions & Divestments' 5-year high stood at $211.0 million during Q4 2020, with a 5-year trough of $8.7 million in Q1 2024.
  • Its 2-year average for Change in Acquisitions & Divestments is $30.6 million, with a median of $36.2 million in 2023.
  • In the last 5 years, Coherus Oncology's Change in Acquisitions & Divestments spiked by 3,807.41% in 2020 and then tumbled by 82.47% in 2021.
  • Coherus Oncology's Change in Acquisitions & Divestments (Quarterly) stood at $211.0 million in 2020, then slumped by 82.47% to $37.0 million in 2021, then reached $36.2 million in 2023, then plummeted by 50.35% to $8.7 million in 2024.
  • Its Change in Acquisitions & Divestments was $8.7 million in Q1 2024, compared to $36.2 million in Q4 2023 and $43.4 million in Q3 2023.